129 related articles for article (PubMed ID: 22029859)
1. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
[TBL] [Abstract][Full Text] [Related]
2. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.
Allaume X; El-Andaloussi N; Leuchs B; Bonifati S; Kulkarni A; Marttila T; Kaufmann JK; Nettelbeck DM; Kleinschmidt J; Rommelaere J; Marchini A
J Virol; 2012 Apr; 86(7):3452-65. PubMed ID: 22258256
[TBL] [Abstract][Full Text] [Related]
3. Immune System Stimulation by Oncolytic Rodent Protoparvoviruses.
Angelova A; Rommelaere J
Viruses; 2019 May; 11(5):. PubMed ID: 31060205
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame.
van Rikxoort M; Michaelis M; Wolschek M; Muster T; Egorov A; Seipelt J; Doerr HW; Cinatl J
PLoS One; 2012; 7(5):e36506. PubMed ID: 22563505
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.
Errington F; White CL; Twigger KR; Rose A; Scott K; Steele L; Ilett LJ; Prestwich R; Pandha HS; Coffey M; Selby P; Vile R; Harrington KJ; Melcher AA
Gene Ther; 2008 Sep; 15(18):1257-70. PubMed ID: 18401435
[TBL] [Abstract][Full Text] [Related]
6. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.
Dempe S; Lavie M; Struyf S; Bhat R; Verbeke H; Paschek S; Berghmans N; Geibig R; Rommelaere J; Van Damme J; Dinsart C
Cancer Immunol Immunother; 2012 Nov; 61(11):2113-23. PubMed ID: 22576056
[TBL] [Abstract][Full Text] [Related]
7. Parvovirus-Based Combinatorial Immunotherapy: A Reinforced Therapeutic Strategy against Poor-Prognosis Solid Cancers.
Angelova A; Ferreira T; Bretscher C; Rommelaere J; Marchini A
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477757
[TBL] [Abstract][Full Text] [Related]
8. Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses.
Vollmers EM; Tattersall P
Virology; 2013 Nov; 446(1-2):37-48. PubMed ID: 24074565
[TBL] [Abstract][Full Text] [Related]
9. On the treatment of melanoma: A mathematical model of oncolytic virotherapy.
Ramaj T; Zou X
Math Biosci; 2023 Nov; 365():109073. PubMed ID: 37660975
[TBL] [Abstract][Full Text] [Related]
10. Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines.
Tilgase A; Grīne L; Blāķe I; Borodušķis M; Rasa A; Alberts P
BMC Res Notes; 2020 Apr; 13(1):222. PubMed ID: 32299493
[TBL] [Abstract][Full Text] [Related]
11. The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics.
Angelova A; Rommelaere J; Ungerechts G
Pathogens; 2024 Feb; 13(3):. PubMed ID: 38535528
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer.
Tran TQ; Grein J; Selman M; Annamalai L; Yearley JH; Blumenschein WM; Sadekova S; Chackerian AA; Phan U; Wong JC
Mol Ther Oncol; 2024 Jun; 32(2):200807. PubMed ID: 38745749
[TBL] [Abstract][Full Text] [Related]
13. AM1172 (a hydrolysis-resistant endocannabinoid analog that inhibits anandamide cellular uptake) reduces the viability of the various melanoma cells, but it exerts significant cytotoxic effects on healthy cells: an in vitro study based on isobolographic analysis.
Marzęda P; Wróblewska-Łuczka P; Florek-Łuszczki M; Góralczyk A; Łuszczki JJ
Pharmacol Rep; 2024 Feb; 76(1):154-170. PubMed ID: 38019413
[TBL] [Abstract][Full Text] [Related]
14. The Future of Interventions for Stage IV Colorectal Cancers.
Lloy S; Lin M; Franko J; Raman S
Clin Colon Rectal Surg; 2024 Mar; 37(2):114-121. PubMed ID: 38327731
[TBL] [Abstract][Full Text] [Related]
15. Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell.
Diao L; Liu M
Adv Sci (Weinh); 2023 Aug; 10(22):e2300121. PubMed ID: 37254712
[TBL] [Abstract][Full Text] [Related]
16. In vitro Characterization of Enhanced Human Immune Responses by GM-CSF Encoding HSV-1-Induced Melanoma Cells.
Delic M; Boeswald V; Goepfert K; Pabst P; Moehler M
Onco Targets Ther; 2022; 15():1291-1307. PubMed ID: 36310770
[TBL] [Abstract][Full Text] [Related]
17. Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits.
Spiesschaert B; Angerer K; Park J; Wollmann G
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298601
[TBL] [Abstract][Full Text] [Related]
18. Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions.
Holbrook MC; Goad DW; Grdzelishvili VZ
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803211
[TBL] [Abstract][Full Text] [Related]
19. Immuno-Oncolytic Viruses: Emerging Options in the Treatment of Colorectal Cancer.
Kana SI; Essani K
Mol Diagn Ther; 2021 May; 25(3):301-313. PubMed ID: 33713031
[TBL] [Abstract][Full Text] [Related]
20. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
